PriceTargets.com logo

Khiron Life Sciences - KHRN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.04 As of 05/6/2023 12:59 AM ET
+0 (0.00%)

This chart shows the closing price for KHRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Khiron Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KHRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KHRN

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Khiron Life Sciences in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.04.

This chart shows the closing price for KHRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Khiron Life Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/30/2022ATB CapitalLower TargetC$0.60 ➝ C$0.45
8/24/2021ATB CapitalLower TargetC$1.00 ➝ C$0.80
5/3/2021ATB CapitalLower TargetC$1.20 ➝ C$1.00
12/1/2020ATB CapitalSet TargetC$1.20
8/25/2020ATB CapitalLower TargetC$1.70 ➝ C$1.60
(Data available from 12/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Khiron Life Sciences logo
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: C$0.04
Low: C$0.04
High: C$0.05

50 Day Range

MA: C$0.04
Low: C$0.04
High: C$0.04

52 Week Range

Now: C$0.04
Low: C$0.04
High: C$0.21

Volume

24,000 shs

Average Volume

256,268 shs

Market Capitalization

C$9.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Khiron Life Sciences?

The following sell-side analysts have issued reports on Khiron Life Sciences in the last twelve months:
View the latest analyst ratings for KHRN.

What is the current price target for Khiron Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Khiron Life Sciences in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Khiron Life Sciences in the next year.
View the latest price targets for KHRN.

What is the current consensus analyst rating for Khiron Life Sciences?

Khiron Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KHRN.

What other companies compete with Khiron Life Sciences?

Other companies that are similar to Khiron Life Sciences include Zomedica Pharmaceuticals Corp. (ZOM.V), InMed Pharmaceuticals, Meta Growth, Decibel Cannabis and MediPharm Labs. Learn More about companies similar to Khiron Life Sciences.

How do I contact Khiron Life Sciences' investor relations team?

Khiron Life Sciences' physical mailing address is 500 Burrard Street, Suite 2300, Vancouver, BC V6C 2B5, Canada, . The company's listed phone number is 705-527-3564. The official website for Khiron Life Sciences is www.khiron.ca. Learn More about contacing Khiron Life Sciences investor relations.